JCB, Volume 17, Number 1, 2011 Editorial Vol.17 No. 1 (2011) Applying design thinking to biotechnology Yali Friedman I was recently invited to assemble a panel on applying design thinking to biotechnology for the conference, ‘A Better World by Design’, hosted by Brown Univers Commentary Vol.17 No. 1 (2011) Building biotechnology by design: An entrepreneur's perspective Arthur A Boni   Commentary Vol.17 No. 1 (2011) Building biotechnology by design: Role of biotechnology in development Patrick Nef   Article Vol.17 No. 1 (2011) Pricing biologics: Issues, strategic priorities and a conceptual model Sanjay K Rao The advent of complex and often expensive biologics raises critical commercial challenges – the most important of which pertains to developing a viable pricing, Article Vol.17 No. 1 (2011) Revitalizing portfolio decision-making at Merck Serono S.A. – Geneva Vincent Aurentz Comprehensive, metric-based portfolio management yields well-known benefits such as increased transparency and the potential for greater objectivity in decision-making. Article Vol.17 No. 1 (2011) Global consensus – Need of the hour for genetically modified organisms (GMO) labeling Jagadeesan Premanandh The controversies surrounding genetically modified organism (GMO) labeling motivated to assess the legitimate concerns of different stakeholders. This article provides Article Vol.17 No. 1 (2011) Beyond investment: Advancing the biotechnology sector in the countries of the Gulf Cooperation Council (GCC) Leonard Lerer Despite substantial investment in healthcare, biomedical education and R&D facilities, the countries of the Gulf Cooperation Council (GCC) face challenges in buildi Case Study Vol.17 No. 1 (2011) Repurposing of the epidermal growth factor Ernesto L Mola This article deals with repurposing of the epidermal growth factor (EGF) to the treatment of diabetic foot ulcers (DFU) grades III and IV, according to the Wagner scale Case Study Vol.17 No. 1 (2011) Biotechnology commercialization: A case study from Central and Eastern Europe Dana Ukropcova A study with generalizable results was conducted on biotechnology commercialization in the region of Central and Eastern Europe. The purpose of this study was to create Case Study Vol.17 No. 1 (2011) The developments in the business models of biotechnology in the Central and Eastern European countries: The example of Estonia Margit Suurna In light of the current debate on the validation of the prevalent business models and trends taking place in the field of biotechnology in developed countries (see here Legal and Regulatory Updates Vol.17 No. 1 (2011) EU Legal and Regulatory Update Gerry Kamstra  Â